BACKGROUND: A disease-specific measure of functional health in syncope would provide an important outcome measure for use either in clinical trials or in the clinical management of patients with recurrent syncope. METHODS AND MEASUREMENTS: In a previous study the authors used formal functional status measures to determine physical and psychosocial impairment in recurrent syncope. This study provides a preliminary assessment of a disease-specific measure of function. The measure was pilot tested on 84 subjects, and validated in a separate cohort of 49 patients. The measure consists of 1) an 11-question matrix of yes/no questions, assessing the ways that syncope interferes with a patient's life (the result is expressed as a proportion of the total number of ways that syncope might interfere and is called the Impairment Score), and 2) three Likert-scale questions that assess the patient's fear and worry about syncope. Correlations were obtained between scores on the disease-specific measure and other measures of functional health. RESULTS: Among the 49 patients in the test cohort, final scores on the disease-specific measure correlated with both physical and psychosocial dimension scores on a measure of functional status, the Sickness Impact Profile (r = 0.35-0.36, p = 0.01), and with five of ten subscale scores on a measure of psychological distress, the Symptom Checklist 90-R (r = 0.30-0.43, p = 0.004-0.02). CONCLUSIONS: This new disease-specific quality-of-life measure in syncope measures both physical and psychosocial components of impairment and could be a valuable adjunct in measuring outcomes in syncope patients.
BACKGROUND: A disease-specific measure of functional health in syncope would provide an important outcome measure for use either in clinical trials or in the clinical management of patients with recurrent syncope. METHODS AND MEASUREMENTS: In a previous study the authors used formal functional status measures to determine physical and psychosocial impairment in recurrent syncope. This study provides a preliminary assessment of a disease-specific measure of function. The measure was pilot tested on 84 subjects, and validated in a separate cohort of 49 patients. The measure consists of 1) an 11-question matrix of yes/no questions, assessing the ways that syncope interferes with a patient's life (the result is expressed as a proportion of the total number of ways that syncope might interfere and is called the Impairment Score), and 2) three Likert-scale questions that assess the patient's fear and worry about syncope. Correlations were obtained between scores on the disease-specific measure and other measures of functional health. RESULTS: Among the 49 patients in the test cohort, final scores on the disease-specific measure correlated with both physical and psychosocial dimension scores on a measure of functional status, the Sickness Impact Profile (r = 0.35-0.36, p = 0.01), and with five of ten subscale scores on a measure of psychological distress, the Symptom Checklist 90-R (r = 0.30-0.43, p = 0.004-0.02). CONCLUSIONS: This new disease-specific quality-of-life measure in syncope measures both physical and psychosocial components of impairment and could be a valuable adjunct in measuring outcomes in syncopepatients.
Authors: J S Sra; A J Anderson; S H Sheikh; B Avitall; P J Tchou; P J Troup; C J Gilbert; M Akhtar; M R Jazayeri Journal: Ann Intern Med Date: 1991-06-15 Impact factor: 25.391
Authors: A L Stewart; S Greenfield; R D Hays; K Wells; W H Rogers; S D Berry; E A McGlynn; J E Ware Journal: JAMA Date: 1989-08-18 Impact factor: 56.272
Authors: Kate Williams; Anja Frei; Anders Vetsch; Fabienne Dobbels; Milo A Puhan; Katja Rüdell Journal: Health Qual Life Outcomes Date: 2012-03-13 Impact factor: 3.186
Authors: Benjamin C Sun; Heather McCreath; Li-Jung Liang; Stephen Bohan; Christopher Baugh; Luna Ragsdale; Sean O Henderson; Carol Clark; Aveh Bastani; Emmett Keeler; Ruopeng An; Carol M Mangione Journal: Ann Emerg Med Date: 2013-11-13 Impact factor: 5.721
Authors: Nynke van Dijk; Kimberly R Boer; Wouter Wieling; Mark Linzer; Mirjam A Sprangers Journal: J Gen Intern Med Date: 2007-07-03 Impact factor: 5.128